Case 2. Tamoxifen and uterine abnormalitiesBUIJS, C; WILLEMSE, P. H. B; TINGA, D. J et al.Journal of clinical oncology. 2004, Vol 22, Num 12, pp 2505-2507, issn 0732-183X, 3 p.Article

Molecular perspectives on selective estrogen receptor modulators (SERMs): progress in understanding their tissue-specific agonist and antagonist actionsLONARD, David M; SMITH, Carolyn L.Steroids. 2002, Vol 67, Num 1, pp 15-24, issn 0039-128XArticle

Hypertriglycéridémie majeure sous tamoxiféne = Severe hypertriglyceridemia under tamoxifenLa Revue Prescrire. 1998, Vol 18, Num 183, pp 281-282, issn 0247-7750Article

Tamoxifen-induced ocular toxicityMIHM, L. M; BARTON, T. L.The Annals of pharmacotherapy. 1994, Vol 28, Num 6, pp 740-742, issn 1060-0280Article

Preclinical and Clinical Pharmacokinetics of PF-02413873, a Nonsteroidal Progesterone Receptor AntagonistBUNGAY, Peter J; TWEEDY, Sarah; HOWE, David C et al.Drug metabolism and disposition. 2011, Vol 39, Num 8, pp 1396-1405, issn 0090-9556, 10 p.Article

The estrogen receptor modulator tamoxifen enhances spontaneous glycinergic synaptic inhibition of hypoglossal motoneuronsCHESNOY-MARCHAIS, D.Endocrinology (Philadelphia). 2005, Vol 146, Num 10, pp 4302-4311, issn 0013-7227, 10 p.Article

Circulating nitric oxide levels increase after anti-androgen treatment in male-to-female transsexualsVALENTI, S; FAZZUOLI, L; GIUSTI, M et al.Journal of endocrinological investigation (Testo stampato). 2003, Vol 26, Num 6, pp 522-526, issn 0391-4097, 5 p.Article

Les modulateurs spécifiques des récepteurs oestrogéniques (SERMs) : Nouvelles thérapeutiques en gynécologie = Specific estrogen receptor modulators (SERMs) : New therapeutics in gynecologyTREMOLLIERES, Florence; LOPES, Patrice.La Presse médicale (1983). 2002, Vol 31, Num 28, pp 1323-1328, issn 0755-4982, 6 p.Article

Effects of the antiestrogen Tamoxifen on low-density lipoprotein concentrations and oxidation in postmenopausal womenGUETTA, V; LUSH, R. M; FIGG, W. D et al.The American journal of cardiology. 1995, Vol 76, Num 14, pp 1072-1073, issn 0002-9149Article

Human Arylacetamide Deacetylase Is a Principal Enzyme in Flutamide HydrolysisWATANABE, Akinobu; FUKAMI, Tatsuki; NAKAJIMA, Miki et al.Drug metabolism and disposition. 2009, Vol 37, Num 7, pp 1513-1520, issn 0090-9556, 8 p.Article

Binding characteristics of aromatase inhibitors and phytoestrogens to human aromataseCHEN, S; KAO, Y.-C; LAUGHTON, C. A et al.Journal of steroid biochemistry and molecular biology. 1997, Vol 61, Num 3-6, pp 107-115, issn 0960-0760Conference Paper

Drug toxicity mechanisms in human hepatoma HepG2 cells : cyclosporin A and tamoxifenDUTHIE, S. J; MELVIN, W. T; BURKE, M. D et al.Xenobiotica (London. Print). 1995, Vol 25, Num 10, pp 1151-1164, issn 0049-8254Article

Speculation on the mechanism of action of triphenylethylene antioestrogensVAN DEN KOEDIJK, C. D. M. A; BLANKENSTEIN, M. A; THIJSSEN, J. H. H et al.Biochemical pharmacology. 1994, Vol 47, Num 11, pp 1927-1937, issn 0006-2952Article

Personalized Tamoxifen: A Step Closer but Miles To GoBARDIA, Aditya; STEARNS, Vered.Clinical cancer research (Print). 2010, Vol 16, Num 17, pp 4308-4310, issn 1078-0432, 3 p.Article

Allergo-immunologie : 2. Les réactions allergiques aux anti-inflammatoires non stéroïdiens : Nouveautés en médecine 2007 (Deuxième partie) = Allergic reactions to nonsteroidal antiinflammatory drugsLEIMGRUBER, A.Revue médicale suisse. 2008, Vol 4, Num 140, pp 100-103, issn 1660-9379, 4 p.Article

Flutamide and cyproterone acetate exert agonist effects: Induction of androgen receptor-dependent neuroprotectionNGUYEN, Thuy-Vi V; MINGZHONG YAO; PIKE, Christian J et al.Endocrinology (Philadelphia). 2007, Vol 148, Num 6, pp 2936-2943, issn 0013-7227, 8 p.Article

Un carcinome lobulaire infiltrant : que proposer après cinq ans de tamoxifène ?La Lettre du sénologue. 2006, Num 31, pp 33-34, issn 1289-2505, 2 p.Article

Safety and adverse effects associated with raloxifene: Multiple Outcomes of Raloxifene EvaluationGRADY, Deborah; ETTINGER, Bruce; MOSCARELLI, Elena et al.Obstetrics and gynecology (New York. 1953). 2004, Vol 104, Num 4, pp 837-844, issn 0029-7844, 8 p.Article

Changes in bone mineral density during and after 3 years' use of tamoxifen or toremifeneTIITINEN, Aila; NIKANDER, Eini; HIETANEN, Päivi et al.Maturitas (Amsterdam). 2004, Vol 48, Num 3, pp 321-327, issn 0378-5122, 7 p.Article

Étude des interférences potentielles entre progestatifs et tamoxifène = Progestins and tamoxifen: interferenceNEVEN, P; LESUR, A.SFSPM : Société française de sénologie et de pathologie mammaire. Journées. 2004, pp 424-434, isbn 2-9520435-6-6, 11 p.Conference Paper

Involvement of PKA and Sp1 in the induction of p27^Kip1 by tamoxifenLEE, Te-Hsiu; CHANG, Hui-Chiu; CHUANG, Lea-Yea et al.Biochemical pharmacology. 2003, Vol 66, Num 3, pp 371-377, issn 0006-2952, 7 p.Article

Tamoxifen decreases lipoprotein(a) in patients with breast cancerSHEWMON, D. A; STOCK, J. L; ABUSAMRA, L. C et al.Metabolism, clinical and experimental. 1994, Vol 43, Num 5, pp 531-532, issn 0026-0495Article

Progesterone receptor binding of steroidal and nonsteroidal compoundsNEELIMA; SETH, M; BHADURI, A. P et al.Progress in drug research. 1986, Vol 30, pp 151-188, issn 0071-786XArticle

Androgen-dependent mechanisms of wolffian duct development and their perturbation by flutamideWELSH, Michelle; SAUNDERS, Philippa T. K; MARCHETTI, Nicholas I et al.Endocrinology (Philadelphia). 2006, Vol 147, Num 10, pp 4820-4830, issn 0013-7227, 11 p.Article

Synergistic interactions between tamoxifen and trastuzumab (Herceptin)ARGIRIS, Athanassios; WANG, Chun-Xia; WHALEN, Steve G et al.Clinical cancer research. 2004, Vol 10, Num 4, pp 1409-1420, issn 1078-0432, 12 p.Article